Literature DB >> 17784819

Antiproliferative activity of the human IFN-alpha-inducible protein IFI44.

L C Hallen1, Y Burki, M Ebeling, C Broger, F Siegrist, K Oroszlan-Szovik, B Bohrmann, U Certa, S Foser.   

Abstract

The interferon-alpha (IFN-alpha)-inducible protein IFI44 is associated with hepatitis C virus (HCV) infection, and its function is unknown. We show here in two human melanoma cell lines (ME15 and D10) that transcription starts 4 h after induction, and peak protein levels are reached 24 h after stimulation. We show by immunofluorescence, viral overexpression, and cellular fractionation that IFI44 is a cytoplasmic protein. Overexpression of IFI44 cDNA induces an antiproliferative state in vitro, even in cells that are not responsive to IFN-alpha. IFI44 contains a perfect GTP binding site but has no homology to known GTPases or G proteins. Based on these results, we propose a model in which IFI44 binds intracellular GTP, and this depletion abolishes extracellular signal-regulated kinase (ERK) signaling and results finally in cell cycle arrest.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17784819     DOI: 10.1089/jir.2007.0021

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  41 in total

1.  Identification of cis- and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles.

Authors:  Ryu Miyagawa; Keiko Tano; Rie Mizuno; Yo Nakamura; Kenichi Ijiri; Randeep Rakwal; Junko Shibato; Yoshinori Masuo; Akila Mayeda; Tetsuro Hirose; Nobuyoshi Akimitsu
Journal:  RNA       Date:  2012-02-21       Impact factor: 4.942

Review 2.  Assessing gene-gene interactions in pharmacogenomics.

Authors:  Hsien-Yuan Lane; Guochuan E Tsai; Eugene Lin
Journal:  Mol Diagn Ther       Date:  2012-02-01       Impact factor: 4.074

3.  Computational Systems Biology of Psoriasis: Are We Ready for the Age of Omics and Systems Biomarkers?

Authors:  Tuba Sevimoglu; Kazim Yalcin Arga
Journal:  OMICS       Date:  2015-10-19

4.  Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences.

Authors:  Claro Yu; Denali Boon; Shannon L McDonald; Timothy G Myers; Keiko Tomioka; Hanh Nguyen; Ronald E Engle; Sugantha Govindarajan; Suzanne U Emerson; Robert H Purcell
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

5.  Identifying gene-gene interactions using penalized tensor regression.

Authors:  Mengyun Wu; Jian Huang; Shuangge Ma
Journal:  Stat Med       Date:  2017-10-16       Impact factor: 2.373

6.  IFI44 suppresses HIV-1 LTR promoter activity and facilitates its latency.

Authors:  Derek Power; Netty Santoso; Michael Dieringer; Jack Yu; Huachao Huang; Sydney Simpson; Ishir Seth; Hongyu Miao; Jian Zhu
Journal:  Virology       Date:  2015-03-14       Impact factor: 3.616

7.  IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells.

Authors:  Scott A Gerber; Jordan S Pober
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

8.  Modulation of interferon activity-associated soluble molecules by appendicitis and appendectomy limits colitis-identification of novel anti-colitic targets.

Authors:  Rajkumar Cheluvappa; Rajaraman Eri; Annie S Luo; Michael C Grimm
Journal:  J Interferon Cytokine Res       Date:  2014-09-22       Impact factor: 2.607

9.  The novel enterochromaffin marker Lmx1a regulates serotonin biosynthesis in enteroendocrine cell lineages downstream of Nkx2.2.

Authors:  Stefanie Gross; Diana C Garofalo; Dina A Balderes; Teresa L Mastracci; José M Dias; Thomas Perlmann; Johan Ericson; Lori Sussel
Journal:  Development       Date:  2016-06-10       Impact factor: 6.868

10.  Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Authors:  Michael Hecker; Christiane Hartmann; Ole Kandulski; Brigitte Katrin Paap; Dirk Koczan; Hans-Juergen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2013-05-01       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.